Andrew Mikhail

Mr. Andrew Mikhail


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
Mats NilssonMats Nilsson
Mats Nilsson
AMAndrew Mikhail
Andrew Mikhail
LLLucy Lan
Lucy Lan
ACAlessia Di Carlo
Alessia Di Carlo
BHBethanie Hamilton
Bethanie Hamilton
mark tarnopolskymark tarnopolsky
mark tarnopolsky
Old age is associated with lower physical activity levels, suboptimal protein intake, and desensitization to anabolic stimuli, predisposing for age-related muscle loss (sarcopenia). Although resistance exercise (RE) and protein supplementation partially protect against sarcopenia under controlled conditions, the efficacy of home-based, unsupervised RE (HBRE) and multi-ingredient supplementation (MIS) is largely unknown. In this randomized, placebo-controlled and double-blind trial, we examined the effects of HBRE/MIS on muscle mass, strength, and function in free-living, older men. Thirty-two sedentary men underwent twelve weeks of home-based resistance band training (3 d/week), in combination with daily intake of a novel five-nutrient supplement (‘Muscle5’; M5, n = 16, 77.4 ± 2.8 y) containing whey, micellar casein, creatine, vitamin D, and omega-3 fatty acids, or an isocaloric/isonitrogenous placebo (PLA; n = 16, 74.4 ± 1.3 y), containing collagen and sunflower oil. Appendicular and total lean mass (ASM; +3%, TLM; +2%), lean mass to fat ratios (ASM/% body fat; +6%, TLM/% body fat; +5%), maximal strength (grip; +8%, leg press; +17%), and function (5-Times Sit-to-Stand time; −9%) were significantly improved in the M5 group following HBRE/MIS therapy (pre vs. post tests; p < 0.05). Fast-twitch muscle fiber cross-sectional areas of the quadriceps muscle were also significantly increased in the M5 group post intervention (Type IIa; +30.9%, Type IIx, +28.5%, p < 0.05). Sub-group analysis indicated even greater gains in total lean mass in sarcopenic individuals following HBRE/MIS therapy (TLM; +1.65 kg/+3.4%, p < 0.05). We conclude that the Muscle5 supplement is a safe, well-tolerated, and effective complement to low-intensity, home-based resistance exercise and improves lean mass, strength, and overall muscle quality in old age.

16 May 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
AMAndrew Mikhail
Andrew Mikhail
PNPeter L. Nagy
Peter L. Nagy
KMKatherine Manta
Katherine Manta
NRNicholas Rouse
Nicholas Rouse
AMAlexander Manta
Alexander Manta
mark tarnopolskymark tarnopolsky
mark tarnopolsky
Background. Myotonic dystrophy type 1 (DM1) is a complex life-limiting neuromuscular disorder characterized by severe skeletal muscle atrophy, weakness, and cardiorespiratory defects. Exercised DM1 mice exhibit numerous physiological benefits that are underpinned by reduced CUG foci and improved alternative splicing. However, the efficacy of physical activity in patients is unknown. Methods. Eleven genetically diagnosed DM1 patients were recruited to examine the extent to which 12 weeks of cycling can recuperate clinical and physiological metrics. Furthermore, we studied the underlying molecular mechanisms through which exercise elicits benefits in skeletal muscle of DM1 patients. RESULTS. DM1 was associated with impaired muscle function, fitness, and lung capacity. Cycling evoked several clinical, physical, and metabolic advantages in DM1 patients. We highlight that exercise-induced molecular and cellular alterations in patients do not conform with previously published data in murine models and propose a significant role of mitochondrial function in DM1 pathology. Finally, we discovered a subset of small nucleolar RNAs (snoRNAs) that correlated to indicators of disease severity. Conclusion. With no available cures, our data support the efficacy of exercise as a primary intervention to partially mitigate the clinical progression of DM1. Additionally, we provide evidence for the involvement of snoRNAs and other noncoding RNAs in DM1 pathophysiology. Trial registration. This trial was approved by the HiREB committee (no. 7901) and registered under ClinicalTrials.gov (NCT04187482). Funding. Neil and Leanne Petroff. Canadian Institutes of Health Research Foundation (no. 143325).

19 April 2023 in Trends in Molecular Medicine
Verified
Journal Article
Open access
AMAndrew Mikhail
Andrew Mikhail
SNSean Y. Ng
Sean Y. Ng
SMStephanie R. Mattina
Stephanie R. Mattina
VLVladimir Ljubicic
Vladimir Ljubicic
Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and spinal muscular atrophy (SMA) are the most prevalent neuromuscular disorders (NMDs) in children and adults. Central to a healthy neuromuscular system are the processes that govern mitochondrial turnover and dynamics, which are regulated by AMP-activated protein kinase (AMPK). Here, we survey mitochondrial stresses that are common between, as well as unique to, DMD, DM1, and SMA, and which may serve as potential therapeutic targets to mitigate neuromuscular disease. We also highlight recent advances that leverage a mutation-agnostic strategy featuring physiological or pharmacological AMPK activation to enhance mitochondrial health in these conditions, as well as identify outstanding questions and opportunities for future pursuit.

10 February 2023 in Acta Physiologica
Verified
Journal Article
Open access
AMAndrew Mikhail
Andrew Mikhail
AMAlexander Manta
Alexander Manta
SNSean Y. Ng
Sean Y. Ng
AOAislin K. Osborne
Aislin K. Osborne
SMStephanie R. Mattina
Stephanie R. Mattina
VLVladimir Ljubicic
Vladimir Ljubicic
Aim: Myotonic dystrophy type 1 (DM1) is the second most common muscular dystrophy after Duchenne and is the most prevalent muscular dystrophy in adults. DM1 patients that participate in aerobic exercise training experience several physiological benefits concomitant with improved muscle mitochondrial function without alterations in typical DM1‐specific disease mechanisms, which suggests that correcting organelle health is key to ameliorate the DM1 pathology. However, our understanding of the molecular mechanisms of mitochondrial turnover and dynamics in DM1 skeletal muscle is lacking.Methods: Skeletal muscle tissue was sampled from healthy and DM1 mice under sedentary conditions and at several recovery time points following an exhaustive treadmill run.Results: We demonstrate that DM1 patients exhibit an imbalance in the transcriptional apparatus for mitochondrial turnover and dynamics in skeletal muscle. Additionally, DM1 mice displayed elevated expression of autophagy and mitophagy regulators. A single dose of exercise successfully enhanced canonical exercise molecular pathways and skeletal muscle mitochondrial biogenesis despite failing to alter the cellular pathology in DM1 mice. However, treadmill running stimulated coordinated organelle fusion and fission signaling, as well as improved alternative splicing of Optic atrophy 1. Exercise also evoked autophagy and mitophagy pathways in DM1 skeletal muscle resulting in the normalized expression of autophagy‐ and lysosome‐related machinery responsible for the clearance of dysfunctional organelles.Conclusion: Collectively, our data indicate that mitochondrial dynamics and turnover processes in DM1 skeletal muscle are initiated with a single dose of exercise, which may underlie the adaptive benefits previously documented in DM1 mice and patients.

10 January 2024 in The FASEB Journal
Verified
Journal Article
Closed access
AHAidan A. Hatt
Aidan A. Hatt
MKMichael Kamal
Michael Kamal
AMAndrew Mikhail
Andrew Mikhail
SFStephen A. Fortino
Stephen A. Fortino
MWMai Wageh
Mai Wageh
GPGianni Parise
Gianni Parise

1 September 2023 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Open access
EWErin K. Webb
Erin K. Webb
SNSean Y. Ng
Sean Y. Ng
AMAndrew Mikhail
Andrew Mikhail
DSDerek W. Stouth
Derek W. Stouth
TVTiffany L. Vanlieshout
Tiffany L. Vanlieshout
VLVladimir Ljubicic
Vladimir Ljubicic
Short-term pharmacological inhibition of coactivator-associated arginine methyltransferase 1 (CARM1) was effective at significantly reducing CARM1 methyltransferase function in skeletal muscle. CARM1 inhibition did not impact muscle mass, but exercise capacity was impaired, particularly in male mice, whereas morphological and molecular signatures of denervation-induced muscle atrophy were largely maintained in animals administered the inhibitor. Altogether, the role of CARM1 in neuromuscular biology remains complex and requires further investigation of its therapeutic potential in muscle-wasting conditions.